Pfizer's Viagra market share in China challenged by Guangzhou Baiyunshan's 'golden spear'

Jin'ge (Chinese for "golden spear") from China's Guangzhou Baiyunshan is said to be on track to eclipse sales of Pfizer's ($PFE) Viagra in China in a few years with a price that is 60% less than the branded erectile dysfunction drug. The company is also said to be looking at taking the copy international. Before Jin'ge hit the market last year, Viagra reportedly had 60% of the market share and Eli Lilly's ($LLY) Cialis held 34.6%, FiercePharmaAsia reports.

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.